Comparison of the predicted population coverage of tuberculosis vaccine candidates Ag85b-ESAT-6, Ag85B-TB10.4, and Mtb72f via a bioinformatics approach

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Davila, Jose ^a   McNamara, Lucy A ^a,b   Yang, Zhenhua ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AG85B ESAT 6; AG85B TB10.4; BCG VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DRB1 ANTIGEN; HLA DRB3 ANTIGEN; HLA DRB4 ANTIGEN; HLA DRB5 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MTB72F; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; ARTIFICIAL NEURAL NETWORK; BIOINFORMATICS; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; EPITOPE MAPPING; GENE FREQUENCY; GENE LOCUS; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; IMMUNE RESPONSE; LUNG TUBERCULOSIS; PREDICTION; PROTEIN BINDING; VACCINE PRODUCTION;

ALLELES; ANTIGENS, BACTERIAL; COMPUTATIONAL BIOLOGY; EPITOPES; HLA ANTIGENS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 84864021810     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040882     Document Type: Article

References (39)

1. Hoft DF, (2008) Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 372: 164-175.
2. Aagaard C, Dietrich J, Doherty M, Andersen P, (2009) TB vaccines: current status and future perspectives. Immunology and cell biology 87: 279-286.
3. Andersen P, (2007) Tuberculosis vaccines- an update. Nature reviews Microbiology 5: 484-487.
4. Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, et al. (2011) A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nature medicine 17: 189-U224.
5. Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P, (2000) ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infection and Immunity 68: 791-795.
6. Dietrich J, Aagaard C, Leah R, Olsen AW, Stryhn A, et al. (2005) Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: Efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. Journal of Immunology 174: 6332-6339.
7. Kaufmann SH, Hussey G, Lambert PH, (2010) New vaccines for tuberculosis. Lancet 375: 2110-2119.
8. Langermans JAM, Doherty TM, Vervenne RAW, van der Laan T, Lyashchenko K, et al. (2005) Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23: 2740-2750.
9. Mustafa AS, Skeiky YA, Al-Attiyah R, Alderson MR, Hewinson RG, et al. (2006) Immunogenicity of Mycobacterium tuberculosis antigens in Mycobacterium bovis BCG-vaccinated and M. bovis-infected cattle. Infection and Immunity 74: 4566-4572.
10. Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P, (2004) Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infection and Immunity 72: 6148-6150.
11. Davila J, Zhang L, Marrs CF, Durmaz R, Yang Z, (2010) Assessment of the genetic diversity of Mycobacterium tuberculosis esxA, esxH, and fbpB genes among clinical isolates and its implication for the future immunization by new tuberculosis subunit vaccines Ag85B-ESAT-6 and Ag85B-TB10.4. Journal of biomedicine & biotechnology 2010: 208371.
12. Hebert AM, Talarico S, Yang D, Durmaz R, Marrs CF, et al. (2007) DNA polymorphisms in the pepA and PPE18 genes among clinical strains of Mycobacterium tuberculosis: Implications for vaccine efficacy. Infection and Immunity 75: 5798-5805.
13. McNamara LA, He YQ, Yang ZH, (2010) Using epitope predictions to evaluate efficacy and population coverage of the Mtb72f vaccine for tuberculosis. Bmc Immunology 11.
14. Brennan MJ, Thole J, (2012) Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis 92: S6-13.
15. Newport MJ, Goetghebuer T, Weiss HA, Whittle H, Siegrist CA, et al. (2004) Genetic regulation of immune responses to vaccines in early life. Genes and immunity 5: 122-129.
16. Blythe MJ, Zhang Q, Vaughan K, de Castro R Jr, Salimi N, et al. (2007) An analysis of the epitope knowledge related to Mycobacteria. Immunome research 3: 10.
17. Contini S, Pallante M, Vejbaesya S, Park MH, Chierakul N, et al. (2008) A model of phenotypic susceptibility to tuberculosis: deficient in silico selection of Mycobacterium tuberculosis epitopes by HLA alleles. Sarcoidosis, vasculitis, and diffuse lung diseases: official journal of WASOG/World Association of Sarcoidosis and Other Granulomatous Disorders 25: 21-28.
18. Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR, (1992) Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proceedings of the National Academy of Sciences of the United States of America 89: 12013-12017.
19. Cho S, Mehra V, Thoma-Uszynski S, Stenger S, Serbina N, et al. (2000) Antimicrobial activity of MHC class I-restricted CD8+ T cells in human tuberculosis. Proceedings of the National Academy of Sciences of the United States of America 97: 12210-12215.
20. van Dissel JT, Arend SM, Prins C, Bang P, Tingskov PN, et al. (2010) Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 28: 3571-3581.
21. AERAS (2012) Vaccine Development. Rockville, MD.
22. Skjot RL, Brock I, Arend SM, Munk ME, Theisen M, et al. (2002) Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infection and Immunity 70: 5446-5453.
23. Skeiky YA, Dietrich J, Lasco TM, Stagliano K, Dheenadhayalan V, et al. (2010) Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine 28: 1084-1093.
24. WHO (2009) Global Tuberculosis Control: Epidemiology, Strategy, Financing.
25. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR, (2011) Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic acids research 39: D913-919.
26. Karosiene E, Lundegaard C, Lund O, Nielsen M, (2011) NetMHCcons: a consensus method for the major histocompatibility complex class I predictions. Immunogenetics.
27. Zhang GL, Ansari HR, Bradley P, Cawley GC, Hertz T, et al. (2011) Machine learning competition in immunology- Prediction of HLA class I binding peptides. Journal of immunological methods 374: 1-4.
28. Sette A, Sidney J, (1999) Nine major HLA class I supertypes account for the vast preponderance of HLA-A and-B polymorphism. Immunogenetics 50: 201-212.
29. Lund O, Nielsen M, Kesmir C, Petersen AG, Lundegaard C, et al. (2004) Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics 55: 797-810.
30. Hughes AJ, Hutchinson P, Gooding T, Freezer NJ, Holdsworth SR, et al. (2005) Diagnosis of Mycobacterium tuberculosis infection using ESAT-6 and intracellular cytokine cytometry. Clinical and Experimental Immunology 142: 132-139.
31. Comas I, Chakravartti J, Small PM, Galagan J, Niemann S, et al. (2010) Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nature Genetics 42: 498-U441.
32. Wang P, Sidney J, Dow C, Mothe B, Sette A, et al. (2008) A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS computational biology 4: e1000048.
33. Nielsen M, Lundegaard C, Blicher T, Peters B, Sette A, et al. (2008) Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan. PLoS computational biology 4.
34. Liu W, Meng X, Xu Q, Flower DR, Li T, (2006) Quantitative prediction of mouse class I MHC peptide binding affinity using support vector machine regression (SVR) models. BMC bioinformatics 7: 182.
35. Wan J, Liu W, Xu Q, Ren Y, Flower DR, et al. (2006) SVRMHC prediction server for MHC-binding peptides. BMC bioinformatics 7: 463.
36. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, et al. (1999) Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nature biotechnology 17: 555-561.
37. Guan P, Doytchinova IA, Zygouri C, Flower DR, (2003) MHCPred: bringing a quantitative dimension to the online prediction of MHC binding. Applied bioinformatics 2: 63-66.
38. Hattotuwagama CK, Guan P, Doytchinova IA, Zygouri C, Flower DR, (2004) Quantitative online prediction of peptide binding to the major histocompatibility complex. Journal of molecular graphics & modelling 22: 195-207.
39. Loffredo JT, Sidney J, Piaskowski S, Szymanski A, Furlott J, et al. (2005) The high frequency Indian rhesus macaque MHC class I molecule, Mamu-B*01, does not appear to be involved in CD8+ T lymphocyte responses to SIVmac239. Journal of Immunology 175: 5986-5997.